Skip to content
OpenCapital
Get started

Oric Pharmaceuticals, Inc. ORIC Current ratio

Current ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
14×-0.4×
CG Oncology logo
CG OncologyCGON
31.3×+0.3×
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
10.9×-4.3×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
6.5×+1.3×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
9×+0.6×

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.0%
Enterprise value$923.07M+23.5%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0×0.0×

Where this comes from

Calculated from Oric Pharmaceuticals, Inc.’s reported figures.

total current assets/total current liabilities=16.3×

Based on the most recent quarter.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s current ratio?
Oric Pharmaceuticals, Inc. (ORIC) reported current ratio of 16.3× in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s current ratio changed year-over-year?
Oric Pharmaceuticals, Inc.'s current ratio increased by 36.1% year-over-year, from 12× to 16.3×.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s current ratio?
Over 5 years (2020 to 2025), Oric Pharmaceuticals, Inc.'s current ratio has grown at a -15.6% compound annual growth rate (CAGR), from 33× to 14.1×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.